Advertisement
News
Advertisement

Use of TIGR® Matrix Surgical Mesh in Multi-Center Randomized Controlled TRAM Flap Study Passes 20 Patient Mark and Wins Praise from Participating Surgeons

Mon, 05/23/2011 - 8:36am
Bio-Medicine.Org

SINGAPORE, May 23, 2011 /PRNewswire/ -- Singapore company Novus Scientific Pte. Ltd announced that the TRAM Flap study (Abdominal Wall Closure After Lipectomy, TRAM/DIEP Flap - Comparison of TIGR® (100% Resorbable) vs Polypropylene (Permanent) Mesh) has passed the 20 patient mark, representing approximately one quarter of the 86 patient study compliment.

This groundbreaking multi-center, randomized trial involves University of California San Diego (UCSD) in the U.S. as well as National University Hospital and Tan Tock Seng Hospital in Singapore. Surgeons from all three study sites will be in attendance at IPRAS 2011, Vancouver, Canada, May 22nd-27th, 2011. Novus Scientific will also be present at IPRAS as an exhibitor at booth 808.

"We are very optimistic about the early results using TIGR®  Matrixin this TRAM Flap study.   TIGR®  Matrix may provide a good option to avoid long-term complications associated with permanent meshes and the high cost of using biological meshes."- James J. Chao, MD FACS, Study Investigator, Professor of Plastic Surgery and Orthopedic Surgery, University of California, San Diego (UCSD) Medical Centre, USA.

"We are proud to have reached this important milestone of the study and it was truly a great team effort by all study investigators in the 3 hospitals. Early results for TIGR®  Matrixlook excellent."- Associate Professor  Thiam Chye Lim, Principal Investigator & Head of Division of Plastic, Reconstructive and Aesthetic Surgery,  National University  Hospital,  Singapore.

"We're very pleased to be part of this important study and with how TIGR®  Matrix

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading